DIAGNOSTIC REPORT

PATIENT NAME : DUMMY PATIENT ID :

ACCESSION NO : 0002UG999999 AGE : 25 Years SEX : Male DATE OF BIRTH :

DRAWN : 30/07/2021 10:09 RECEIVED : 30/07/2021 10:09 REPORTED : 31/07/2021 10:09

REFERRING DOCTOR : CLIENT PATIENT ID :

Passport No : :

Test Report Status Final Results Biological Reference Interval Units

FEVER PANEL – ADVANCE

BLOOD COUNTS
HEMOGLOBIN 13.0 - 17.0 g/dL
RED BLOOD CELL COUNT 4.5 - 5.5 mil/µL
WHITE BLOOD CELL COUNT 4.0 - 10.0 thou/µL
PLATELET COUNT 150 - 410 thou/µL
RBC AND PLATELET INDICES
HEMATOCRIT 40 - 50 %
MEAN CORPUSCULAR VOLUME 83.0 - 101.0 fL
MEAN CORPUSCULAR HEMOGLOBIN 27.0 - 32.0 pg
MEAN CORPUSCULAR HEMOGLOBIN 31.5 - 34.5 g/dL
CONCENTRATION
RED CELL DISTRIBUTION WIDTH 11.6 - 14.0 %
MEAN PLATELET VOLUME 6.8 - 10.9 fL
WBC DIFFERENTIAL COUNT
NEUTROPHILS 40 - 80 %
ABSOLUTE NEUTROPHIL COUNT 2.0 - 7.0 thou/µL
EOSINOPHILS 1-6 %
ABSOLUTE EOSINOPHIL COUNT 0.02 - 0.50 thou/µL
LYMPHOCYTES 20 - 40 %
ABSOLUTE LYMPHOCYTE COUNT 1.0 - 3.0 thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR)
MONOCYTES 2 - 10 %
ABSOLUTE MONOCYTE COUNT 0.2 - 1.0 thou/µL
BASOPHILS <1-2 %
ABSOLUTE BASOPHIL COUNT 0.02 - 0.10 thou/µL
LARGE UNSTAINED CELLS (LUC) %
BAND (STAB) CELLS %
METAMYELOCYTE %
MYELOCYTES %
PROMYELOCYTES %
BLASTS %
DIFFERENTIAL COUNT PERFORMED ON:
MORPHOLOGY
RBC
WBC

Page 1 Of 3
 DIAGNOSTIC REPORT

PATIENT NAME : DUMMY PATIENT ID :

ACCESSION NO : 0002UG999999 AGE : 25 Years SEX : Male DATE OF BIRTH :

DRAWN : 30/07/2021 10:09 RECEIVED : 30/07/2021 10:09 REPORTED : 31/07/2021 10:09

REFERRING DOCTOR : CLIENT PATIENT ID :

Passport No : :

Test Report Status Final Results Biological Reference Interval Units

PLATELETS
IMPRESSION
NUCLEATED RBCS /100 WBC'S
REMARKS
DENGUE NS1 ANTIGEN TEST, SERUM
DENGUE NS1 ANTIGEN ELISA
MALARIA ANTIGEN DETECTION, WHOLE BLOOD
PLASMODIUM FALCIPARUM ANTIGEN
PLASMODIUM VIVAX ANTIGEN

Interpretation(s)
WBC DIFFERENTIAL COUNT-

The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years
old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to
show mild disease.
(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504
This ratio element is a calculated parameter and out of NABL scope.
DENGUE NS1 ANTIGEN TEST, SERUM-
Dengue virus is transmitted by Aedes mosquitoes. It belongs to the genus Flavivirus and has four serotypes, DEN-1, DEN-2, DEN-3, and DEN-4. Infection with one dengue
serotype provides lifelong immunity to that virus, but no cross protective immunity to the other serotypes. Human dengue infection causes a spectrum of illnesses ranging
from inapparent or mild febrile illness to severe to fatal hemorrhagic disease. WHO classifies dengue infections as primary or secondary. It is believed that patients
experiencing a secondary infection with heterologous serotypes have higher risk of complications, including Dengue Haemorrhagic Fever (DHF) and Dengue Shock Syndrome
(DSS).

Test Utility:
Dengue NS1 antigen can be detected in serum from day 1 after onset of clinical signs, up to day 9. Dengue specific IgM can be detected as early as 5 days after the onset of
fever and generally persists for 30-90 days, although detectable levels may be present rarely upto 8 months post-infection. IgM antibody is also produced in secondary and
tertiary dengue infections, although the response in some secondary and probably most tertiary infections is low level and transient. Dengue IgG levels usually start rising at
the end of 1st week in primary infection and persists for months and sometimes for life.
Patients with primary dengue infections usually are IgM positive & IgG negative with higher IgM concentrations, whereas patients with secondary infections are usually both
IgG and IgM positive with higher IgG concentrations.

Confirmed diagnosis of Dengue fever can be established in a suspected case with atleast one of the following tests:
1) Demonstration of NS1 antigen by ELISA
2) Demonstration of IgM antibody titre by ELISA in single serum sample,
3) IgG seroconversion in paired sera after 2 weeks with 4 fold rise in titre
4) Demonstration of viral nucleic acid by PCR

Limitations:
• Cross reactivity due to other flaviviruses infections (Tick-borne encephalitis, Japanese encephalitis etc) can give false positive dengue test.
• Differential diagnoses during the acute phase of illness should include measles, rubella, influenza, typhoid, leptospirosis, malaria, other viral hemorrhagic fevers, and any
other disease that may present as a nonspecific viral syndrome.
MALARIA ANTIGEN DETECTION, WHOLE BLOOD-
MALARIA ANTIGEN DETECTION, BLOOD

Four species of the plasmodium parasites are responsible for human malaria infections; P. falciparum, P. vivax, P. ovale and P. malariae. P. falciparum and P. vivax are the
most prevalent. Early detection and differentiation of malaria is of paramount importance due to incidence of cerebral malaria and drug resistance associated with P.
falciparum malaria causing most of the morbidity and mortality worldwide .As treatment depends on the species, differential diagnosis of P. falciparum and P. vivax is
extremely important for better patient care management and faster recovery.

Test Utility:
The current test is a qualitative test for detection of the P. falciparum specific histidine rich protein-2 (Pf. HRP-2) and P. vivax specific lactate dehydrogenase (pLDH) in whole
blood samples. The assay is able to detect and distinguish P. vivax and P. falciparum infections and also identify mixed infections.

Notes & Limitations:

¿ In case of a suspected P. falciparum case, a positive band for Pf. HRP-2 is highly predictive of infection, but a negative test result may not rule out the same. This may be
seen in patients with i) very low parasitic index (<5 parasites/HPF), as the test sensitivity and test band intensity correlated directly with the parasite density, and i) Carriers,
as Pf. HRP-2 is not secreted in the gametogony (sexual) stage. Rarely, a false negative result may be seen in individuals with a gene deletion for the production of HRP-2.
¿ Pf. HRP-2 persists after successful therapy and may be detectable even after the clinical symptoms of malaria have disappeared and the parasites have apparently been
cleared from the host. Hence it should not be used for monitoring early therapeutic responses.
¿ In case of a stand alone P. vivax infection, the band for pLDH may be used to monitor patient progress during therapy and predict recrudescence and possible drug-resistant
infections. In case the pLDH band remains positive with the same intensity after 5-10 days, the possibility of a resistant strain has to be considered. A negative pLDH result

Page 2 Of 3
 DIAGNOSTIC REPORT

PATIENT NAME : DUMMY PATIENT ID :

ACCESSION NO : 0002UG999999 AGE : 25 Years SEX : Male DATE OF BIRTH :

DRAWN : 30/07/2021 10:09 RECEIVED : 30/07/2021 10:09 REPORTED : 31/07/2021 10:09

REFERRING DOCTOR : CLIENT PATIENT ID :

Passport No : :

Test Report Status Final Results Biological Reference Interval Units

does not rule out P. vivax infection, as may be seen in patients with a very low parasitic index (<5 parasites/HPF).
Since the test detects P. falciparum specific HRP-2 and P. vivax specific LDH, a negative test result does not rule out infection with P. ovale and P. malariae.
¿ Constant exposure to the malarial parasites, as seen in areas of high endemicity, may result in positive results with doubtful clinical significance. Hence, the results must
always be correlated with clinical history and relevant epidemiological and therapeutic context. Also note that blood film examination remains the standard method for
diagnosing malaria, since it detects all Plasmodium spp. and allows visualization of parasite growth stages, which is essential for making therapeutic decisions.
**End Of Report**
Please visit www.srlworld.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

1. It is presumed that the test sample belongs to the patient 5. The results of a laboratory test are dependent on the
named or identified in the test requisition form.
2. All Tests are performed and reported as per the
turnaround time stated in the SRL Directory of services
(DOS).
3. SRL confirms that all tests have been performed or
assayed with highest quality standards, clinical safety &
technical integrity.
4. A requested test might not be performed if:
a. Specimen received is insufficient or inappropriate
specimen quality is unsatisfactory
b. Incorrect specimen type
c. Request for testing is withdrawn by the ordering doctor investigation repeat analysis may be carried out.
or patient
d. There is a discrepancy between the label on the
specimen container and the name on the test requisition
form
quality of the sample as well as the assay technology.
6. Result delays could be because of uncontrolled
circumstances. e.g. assay run failure.
7. Tests parameters marked by asterisks are excluded from
the “scope" of NABL accredited tests. (If laboratory is
accredited).
8. Laboratory results should be correlated with clinical
information to determine Final diagnosis.
9. Test results are not valid for Medico- legal purposes.
10. In case of queries or unexpected test results please call
at SRL customer care (91115 91115). Post proper
SRL Limited
Fortis Hospital, Sector 62, Phase VIII,
Mohali 160062

Page 3 Of 3